SCHEMBL2441052

SCHEMBL2441052

O=P(Oc1ccccc1)(Oc1ccccc1)Oc1noc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.42
MGLL Q99685 1/20 0.42
HIF1A Q16665 4/20 0.40
EPHX2 P34913 5/20 0.39
SRC P12931 1/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ACHE P22303 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
LMNA P02545 1/20 0.36
CA3 P07451 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
MAOB P27338 1/20 0.36
CA5A P35218 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9035692 0.76 FAAH (0.49) FAAHMGLLHIF1AEPHX2MAPT
Triphenyl Phosphate SCHEMBL28761613 0.73 SRC (0.64) SRCTDP1L3MBTL1LMNA
Triphenyl Phosphate SCHEMBL28557783 0.73 SRC (0.64) SRCTDP1L3MBTL1LMNA
Triphenyl Phosphate SCHEMBL483692 0.73 SRC (0.64) SRCTDP1L3MBTL1LMNA
Triphenyl Phosphate SCHEMBL18116 0.73 SRC (0.64) SRCTDP1L3MBTL1LMNA
SCHEMBL3716873 0.72 SRC (0.38) SRCMAPTSMN1; SMN2TDP1L3MBTL1
Triphenyl Phosphate SCHEMBL9576987 0.71 SRC (0.61) SRCTDP1L3MBTL1LMNA
Triphenyl Phosphate SCHEMBL7746390 0.71 SRC (0.61) SRCTDP1L3MBTL1LMNA
Triphenyl Phosphate SCHEMBL15815456 0.71 SRC (0.61) SRCTDP1L3MBTL1LMNA
Triphenyl Phosphate SCHEMBL2530073 0.71 SRC (0.61) SRCTDP1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1684816-B1 METHODS OF PREPARING CROSSLINKED MATERIALS AND BIOPROSTHETIC DEVICES MEDTRONIC INC (US) 2009-05-06 EP claimed
US-20090023698-A1 METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID KRASUTSKY PAVEL A 2009-01-22 US claimed
US-20080171906-A1 TISSUE PERFORMANCE VIA HYDROLYSIS AND CROSS-LINKING MEDTRONIC, INC. 2008-07-17 US claimed
EP-1684816-A2 METHODS OF PREPARING CROSSLINKED MATERIALS AND BIOPROSTHETIC DEVICES Medtronic, Inc. (US) 2006-08-02 EP claimed
US-7053051-B2 Methods of preparing crosslinked materials and bioprosthetic devices MEDTRONIC, INC. (US) 2006-05-30 US claimed
US-20050136510-A1 Methods of preparing crosslinked materials and bioprosthetic devices MEDTRONIC, INC. 2005-06-23 US claimed
WO-2005042043-A2 METHODS OF PREPARING CROSSLINKED MATERIALS AND BIOPROSTHETIC DEVICES MEDTRONIC, INC. (US) 2005-05-12 WO claimed
EP-0898973-B1 A method of making a crosslinked collagen-based material and bioprosthetic devices produced therefrom MEDTRONIC INC (US) 2005-01-19 EP claimed
EP-0897942-B1 A method of crosslinking collagen-based material and bioprosthetic devices produced therefrom MEDTRONIC INC (US) 2004-03-10 EP claimed
US-6166184-A Process for making a bioprosthetic device MEDTRONIC INC. (US) 2000-12-26 US claimed
US-6117979-A MIXING AN EPOXY FUNCTIONALIZED CROSSLINKING AGENT WITH COLLAGEN-BASED MATERIAL IN AQUEOUS MEDIUM AT ACIDIC PH; COLLAGEN CARBOXYL GROUPS REACT WITH AGENT; HEART VALVES WITH GOOD MECHANICAL PROPERTIES, RETAIN FLEXIBILITY MEDTRONIC, INC. (US) 2000-09-12 US claimed
EP-0898973-A2 A method of making a crosslinked collagen-based material and bioprosthetic devices produced therefrom MEDTRONIC, INC. (US) 1999-03-03 EP claimed
EP-0897942-A1 A method of crosslinking collagen-based material and bioprosthetic devices produced therefrom MEDTRONIC, INC. (US) 1999-02-24 EP claimed
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF INSTITUT CURIE (FR) 2026-05-21 US disclosed
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof INSTITUT CURIE (FR) 2026-01-20 US disclosed
US-20250340559-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS INCYTE HOLDINGS CORP (US) 2025-11-06 US disclosed
EP-0897942-A1 A method of crosslinking collagen-based material and bioprosthetic devices produced therefrom MEDTRONIC, INC. (US) 1999-02-24 EP disclosed
US-5015698-A Polyphenylene ether-polyester copolymers, precursors therefor, compositions containing said copolymers, and methods for their preparation GENERAL ELECTRIC COMPANY (US) 1991-05-14 US disclosed
EP-0248263-A2 Polyphenylene ether-polyester copolymers precursors therefor, compositions containing said copolymers, and methods for their preparation GENERAL ELECTRIC COMPANY (US) 1987-12-09 EP disclosed
WO-1987007279-A1 POLYPHENYLENE ETHER-POLYESTER COPOLYMERS, PRECURSORS THEREFOR, COMPOSITIONS CONTAINING SAID COPOLYMERS, AND METHODS FOR THEIR PREPARATION GENERAL ELECTRIC COMPANY (US) 1987-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12527854-B2 Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof STXBP1, RNGTT, UPF1 FAAH 4265/4885MGLL 3171/4885HIF1A 2297/4885
US-20260137765-A1 METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF STXBP1, HBB, UPF1 FAAH 3932/4885MGLL 2950/4885HIF1A 1274/4885
US-20090023698-A1 METHODS OF MANUFACTURING BIOACTIVE 3-ESTERS OF BETULINIC ALDEHYDE AND BETULINIC ACID BET1, ALDH7A1, CA7 FAAH 301/4885MGLL 1744/4885HIF1A 283/4885
US-20250340559-A1 PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS JAK3, JAK1, JAK2 FAAH 4414/4885MGLL 4318/4885HIF1A 2870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.